All In Biotech

Drug Trial Radar · NCT01168375

The Role of Umbilical Cord Serum Therapy on Improvement of Corneal Epithelial Defect Following Diabetic Vitrectomy

Last checked: Nov 20, 2026Latest source record: Jul 23, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

Not stated

Start

Not stated

Primary completion

Not stated

Sponsor

Lead sponsor
Shahid Beheshti University of Medical SciencesAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ophthalmic Research Center
First posted
Jul 23, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

80 diabetic patients underwent vitrectomy and had no history of Eye herpes infection, Refractive surgery, Autoimmune disease, Immune deficiency will be randomized into two groups (double blind)to evaluate the role of umbilical cord serum therapy on improvement of corneal epithelial defect following diabetic vitrectomy. Both groups will take the conventional medication including Chloramphenicol, Betamethasone, Cycloplegic eye drops besides the case group will take umbilical cord serum eye drop in the eye operated. After surgery the corneal epithelial defect will be measured by slit lamp.

Conditions

  • Corneal Epithelial Defect

Interventions

  • conventional therapy plus umbilical cord serum eye dropDrug

    chloramphenicol and betamethasone eye drops every 6 hours, cycloplegic (homatropine) eye drop every 8 hours plus umbilical cord serum eye drop 20% every 4 hours

  • conventional therapyDrug

    chloramphenicol and betamethasone eye drops every 6 hours, cycloplegic (homatropine) eye drop every 8 hours

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. measurement of corneal epithelial defect

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ophthalmic Research Center

    Tehran, Tehran Province, Iran

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.